Background: Glaucoma is a leading cause of irreversible blindness. The fundamental problem in medical management of glaucoma is of patient compliance. An ideal drug or a drug combination is needed to slow the progression of this majorly symptomless disease.
INTRODUCTION
Glaucoma refers to a heterogeneous group of ocular disorders that affect the optic nerve and involves a loss of
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retinal ganglion cells in a characteristic pattern, usually with correlating visual field defects. The common denominator of glaucoma is a characteristic optic neuropathy, which derives from various risk factors, including increased Intraocular pressure (IOP). 1 Glaucoma is a leading cause of irreversible blindness. 2 Statistics gathered by WHO in 2002, and published, 3 show that glaucoma is the second leading cause of blindness globally, after cataracts. Data from population-based surveys indicate that one in 40 adults older than 40 years has glaucoma with loss of visual function, which equates to 60 million people worldwide being affected and 8 to 14 million being bilaterally blind. 4 Even in developed countries, half of glaucoma cases are undiagnosed. In India it is estimated that there are approximately 11.2 million persons aged 40 years and older with glaucoma. Primary open angle glaucoma (POAG) is estimated to affect 6.48 million persons. 5 Elevated IOP is the most important causative risk factor for development and progression of POAG and it is the only treatable risk factor for open angle glaucoma. 6 A current treatment strategy is to set a target pressure for the patient to achieve, the target pressure chosen can vary based on patients age, race and disease progression, status of the optic nerve head, central corneal thickness, vascular factors but it should be less than IOP at which optic nerve damage and visual loss occurs. It is conventional practice to lower the IOP by at least one-third once glaucomatous optic neuropathy is detected. 7 The therapeutic arsenal available has recently been extended with the addition of new ocular hypotensive agents like prostaglandin derivatives, local CAIs and alpha-2 adrenergic agonists. 8 Both timolol and latanoprost are being widely used as first line drugs in glaucoma, due to their high efficacy and limited side effect profile. Dorzolamide is another potent drug used in the treatment of glaucoma as it not only decreases the IOP but also improves ocular perfusion. In spite of having good potency, these drugs are sometimes unable to lower the IOP when used as a monotherapy and adding another drug to the therapy is required. However, 
MATERIALS AND METHODS

Study Design
A randomized 12-week, parallel group, open study was conducted in Department of Pharmacology in association with Department of Ophthalmology at MMIMSR, Mullana.
The study protocol was approved before the commencement of the study by the institutional ethics committee. The study was in accordance with standards set in declaration of Helsinki of 1975. All the patients gave their consent before enrolment in the study. As patients enrolled in the trial, they were randomized according to a computer generated randomization schedule. The drop-outs were not taken into consideration as it was an intention-totreat trial.
50 POAG patients, fulfilling all of inclusion criteria and exclusion criteria were selected and one eye of bilateral POAG cases was taken up as study eye.
Inclusion criteria were a male or female patient with a minimum age 25 years having a history of unilateral or bilateral primary open angle glaucoma or ocular hypertension with IOP > 22 mm Hg, diagnosed by applanation tonometry and gonioscopy, requiring pharmacological therapy, showing inadequate response to monotherapy (target IOP not achieved) and having corrected visual acuity 20/40 or greater. Gonioscopy was done to diagnose open angle glaucoma.
Exclusion criteria included the patient being diagnosed as closed anterior chamber angle, ocular injury, ocular surgery within previous 6 months, allergy to study drugs, ocular infection and other systemic illnesses.
Washout period was given to patients and varied from 1 week for patients on cholinergic agonists and CA inhibitors to 2 weeks for patients on adrenergic receptor agonists to 4 weeks for patients on beta adrenergic antagonists or prostaglandins. Patients returned weekly for IOP monitoring during this period.
Study visits included day 0 (baseline visit), 2, 4 and 12 weeks. Prestudy examination (an investigation for baseline data) included medical history, ocular history, treatment history, complete ocular examination including visual acuity, intraocular pressure, oblique examination, slitlamp examination, gonisocopy, visual fields and systemic examination.
After attaining the baseline data patients were put on treatment accordingly.
Study Drugs
• Latim eye drops (Fixed combination of latanopost 0.05% and timolol 0.5%) once a day in the evening.
• Dorzox T eye drops (Fixed combination of dorzolamide 2% and timolol 0.5%) twice daily morning and evening. Group 1 included patients diagnosed as primary open angle glaucoma/ocular hypertension with IOP > 22 mm Hg and were instilled fixed combination of latanoprost 0.05% and timolol 0.5% once a day in the evening for 12 weeks.
Group 2 included patients diagnosed as primary open angle glaucoma/ocular hypertension with IOP > 22 mm Hg instilled fixed combination of dorzolamide 2% and timolol ophthalmic solution 0.5% twice daily for 12 weeks.
IOP observations were made at, 2nd, 4th and 12th week by the same investigator each time. IOP was taken at both 9 AM and 12 noon. Other parameters recorded on subsequent visits: Visual acuity, cup to disk ratio, visual fields, conjunctival hyperemia, blood pressure, pulse rate.
At each visit, the patients were asked about any adverse drug reactions. Any adverse events reported by the patient or investigator were recorded and analyzed. Safety/tolerability evaluation was based upon self-reported adverse effects.
The primary end-point included reduction in IOP from baseline to week 12. Data were collected and the analysis of each variable was performed on the change from baseline values using two tailed Student t-test. A p-value less than or equal to 0.05 was considered statistically significant. In addition, the demographic variables were analyzed using Pearson's Chi-square test.
RESULTS
Fifty patients were randomized to group 1, who instilled fixed combination of 0.005 latanoprost and 0.5% timolol once daily and group 2 in whom 2% dorzolamide + timolol 0.5% twice daily was prescribed.
Treatment groups were statistically similar at baseline. In group 1 the age of patients ranged from 40 to 70 years with the mean age of 55.28 ± 8.87 years. In group 2 the age of patients ranged from 42 to 80 years with the mean age of 56.60 ± 10.51 years.
There was no statistically significant difference between the ages of the patients of the two groups (p = 0.6). The difference in male female ratio was also not statistically significant between the two groups (p = 0.382) ( Table 1) .
In group 1 at 9.00 AM the mean IOP decreased from 27.88 ± 2.18 to 17.92 ± 0.86 mm Hg, thus resulting in a fall of 9.96 mm Hg (35.82%). Whereas at 12 am the mean IOP decreased from 27.72 ± 2.30 to 17.84 ± 0.688 mm Hg resulting in a fall of 9.88 mm Hg (35.53%). The fall of IOP was statistically significant at all time intervals on all visits.
In-group 2 at 9 AM the mean IOP decreased from 27.56 ± 2.10 to 18.52 ± 0.770 mm Hg which amounts to fall of 9.04 mm Hg (32.51%). Whereas at 12 AM the mean IOP was reduced from the baseline of 27.92 ± 2.43 to 18.52 ± 0.770 mm Hg thus, resulting in a fall of 9.40 mm Hg (33.81%) (Graphs 1 and 2 ). The fall of IOP was statistically significant at all time intervals.
The difference in final IOP achieved in the two groups was not statistically significant for 2 and 4 weeks periods but at week 12 the latanoprost/timolol combination showed more efficacy. The decrease in mean diunal IOP from baseline to 12 weeks in group 1 was 9.920 ± 2.519. In group 2 this reduction was 9.220 ± 2.25. The difference in IOP reduction between two groups was statistically significant at 12 weeks (p = 0.004) ( Table 2) .
The mean CD ratio in group 1 increased from mean of 0.592 ± 0.1498. to 0.600 ± 0.1581. In group 2, the mean CD ratio increased from baseline of 0.624 ± 0.1422 to 0.632 ± 0.1520. However, the increase of CD ratio in both groups was statistically not significant (p = 0.161).
The mean visual acuity in group 1 decreased from 1.304 ± 2.652 to 1.296 ± 2.655 and in group 2, it decreased from 0.740 ± 0.200 to 0.716 ± 0.2304. However, the decrease in visual acuity was statistically not significant in both the groups (p = 0.327, 0.185 respectively).
In general both the fixed combinations were well tolerated although more patients treated with dorzolamide/ timolol FC reported eye pain after ocular instillation. Latanoprost/timolol was associated with more frequent conjunctival hyperemia. There was no significant differences in drug related ocular or systemic side effects, both the FCs were well tolerated (Table 3) .
DISCUSSION
IOP is the only modifiable risk factor in POAG and medical therapy is the first therapeutic approach. In all patients IOP may not be controlled with monotherapy and adjunctive 
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therapy may be required. To improve compliance and convenience to the patient two drugs can be given in a fixed combination of the two individual components. In this 12 weeks study, the reduction in IOP brought about by the drugs in both groups 1 and 2 was statistically significant at all time intervals. The difference in final IOP achieved in the two groups was not statistically significant for 2 and 4 weeks periods but at week 12 the latanoprost/ timolol combination showed more efficacy. The decrease in IOP from baseline to 12 weeks in group 1 was 9.960 and 9.880 at 9 AM and 12 noon respectively. In group 2, this decrease was 9.040 and 9.400. The difference in IOP reduction between two groups was statistically significant at 12 weeks for both time readings (p = 0.013 and 0.002 respectively.
In a study done by Miglior et al 14, 15 in 2009, compared the efficacy of FC latanoprost/timolol and FC dorzolamidetimolol. It was found that mean reductions in daytime IOP from baseline to week 12 was by -9.7 mm Hg for FC latanoprost-timolol and -9.5 mm Hg for FC dorzolamide/ timolol, indicating that neither FC is inferior to the other. The results of this study parallels the result of a 3-month, randomized, parallel-group, evaluator-masked study, 16 in 253 subjects, in which it was found that FC latanoprost/ timolol reduced the mean daytime IOP by 1 mm Hg more than the comparator (p = 0.005) and the mean IOP levels after 3 months of treatment were significantly lower in the FC latanoprost/timolol group at 0800 and 1600 hours (p < 0.01 for both comparisons). Cvenkel et al 17 did a similar study in 2008 and found that patients treated with dorzolamide/timolol FC and latanoprost/timolol FC have no statistically similar ocular hypotensive effect. Both FC agents were well tolerated. In all, six out of 25 (25.9%) subjects in the FC latanoprost/timolol group and seven out of 25 (30.4%) in the FC dorzolamide/timolol group reported adverse events. The most frequently occurring adverse events related to study medications were eye pain, eye irritation, conjunctival hyperemia, and taste disturbance, which were not long lasting. The most commonly noted ocular adverse events in the FC latanoprost/timolol group were eye pruritus and conjunctival hyperemia; most frequently reported ocular adverse events in the FC dorzolamide/timolol group were eye pain, blurred vision, stinging, dry eyes. In general, both fixed-combination drugs were well tolerated. Since, one drug was given once a day and the other twice a day this study could not be blinded which was a limitation of this study.
CONCLUSION
From our study, it can be concluded that IOP lowering efficacy of latanoprost/timolol is superior to dorzolamide/ timolol.
In general both the fixed combinations were well tolerated. There was no significant differences in drug related ocular or systemic side effects.
However, given the small differences in IOP lowering between the two therapies, assessing the effects of differences in dosing and tolerability on patient compliance and patient outcomes should be the goals of further research. 
